查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1379173

血液惡性腫瘤市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年，全球血液惡性腫瘤市場規模達到553億美元。展望未來， IMARC Group預計到2028年市場規模將達到932億美元，2022-2028年複合年成長率（CAGR）為9.1%。

血液惡性腫瘤，如淋巴瘤、白血病和多發性骨髓瘤，是造血細胞的癌症。這些細胞包括用於凝血傷口的血小板、攜帶氧氣的紅血球 (RBC) 和用於免疫保護的白血球 (WBC)，這些細胞源自骨髓中的造血幹細胞和祖細胞。血液惡性腫瘤可以透過顯微鏡、細胞遺傳學、免疫表現型、流式細胞儀、螢光原位雜合技術 (FISH)、聚合酶鍊式反應 (PCR) 和基因表現譜等測試來診斷。如今，世界各地有多種藥物可用於基於診斷測試的治療，包括抗腫瘤抗生素、組蛋白去乙醯化酶抑制劑和 Janus 激酶 (JAK) 抑制劑。

血液惡性腫瘤市場趨勢：

老年族群中急性髓性白血病（AML）的發生率相對較高。這與預期壽命的延長相結合，是推動全球血液惡性腫瘤藥物需求的關鍵因素之一。除此之外，隨著免疫組織化學（IHC）的進步，透過將組織樣本暴露於針對細胞分子和抗原的各種抗體，可以準確診斷血液惡性腫瘤。這反過來又加強了市場的成長。此外，人們對早期診斷的認知不斷提高，加上診斷方式的改進，也促進了市場的成長。除此之外，手術治療還可用於組織診斷和治療淋巴瘤併發症，例如穿孔、阻塞和狹窄。這與多種新療法的推出以及高價藥物的多個標籤擴展（例如 CAR T 細胞療法和 brexucabtagene autoleuce）相結合，正在推動市場成長。此外，正在進行的為晚期血液惡性腫瘤患者引入先進藥物的臨床研究預計將在未來幾年推動市場發展。

本報告回答的關鍵問題：

  • 迄今為止，全球血液惡性腫瘤市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球血液惡性腫瘤市場有何影響？
  • 主要區域市場有哪些？
  • 依類型分類市場是怎麼樣的？
  • 基於該療法的市場區隔是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球血液惡性腫瘤市場的結構如何？誰是主要參與者？
  • 產業競爭程度如何？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球血液惡性腫瘤市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按類型分類的市場細分

  • 白血病
    • 市場走向
    • 市場預測
  • 淋巴瘤
    • 市場走向
    • 市場預測
  • 多發骨髓瘤
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：透過療法進行市場區隔

  • 化療
    • 市場走向
    • 市場預測
  • 放射治療
    • 市場走向
    • 市場預測
  • 免疫療法
    • 市場走向
    • 市場預測
  • 幹細胞移植
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：最終用戶的市場區隔

  • 醫院
    • 市場走向
    • 市場預測
  • 診斷中心
    • 市場走向
    • 市場預測
  • 研究中心
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：按地區分類的市場區隔

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112023A4133

Abstract

The global hematologic malignancies market size reached US$ 55.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 93.2 Billion by 2028, exhibiting a growth rate (CAGR) of 9.1% during 2022-2028.

Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.

Hematologic Malignancies Market Trends:

The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapy and end user.

Breakup by Type:

Leukemia

Lymphoma

Multiple Myeloma

Others

Breakup by Therapy:

Chemotherapy

Radiotherapy

Immunotherapy

Stem Cell Transplantation

Others

Breakup by End User:

Hospitals

Diagnostics Centers

Research Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Leukemia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Stem Cell Transplantation
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck & Co. Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
  • Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2022
  • Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2022
  • Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
  • Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
  • Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
  • Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Hematologic Malignancies Market: Competitive Structure
  • Table 7: Global: Hematologic Malignancies Market: Key Players